Benchmark Maintains Buy on Agilon Health, Lowers Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bill Sutherland has maintained a Buy rating on Agilon Health (NYSE:AGL) but reduced the price target from $28 to $22.

November 15, 2023 | 2:24 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Benchmark analyst Bill Sutherland maintains a Buy rating on Agilon Health but lowers the price target from $28 to $22.
While the reduction in price target could suggest a more conservative outlook on the stock's valuation, the maintenance of a Buy rating indicates that the analyst still sees positive fundamentals in the company. This mixed signal may lead to a neutral short-term impact on the stock price as investors digest both the continued endorsement and the lowered expectations.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100